Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Food on Maribavir PK in Healthy Adults
NCT05382104Phase 1Completed
- Sponsor
- Takeda
- Start
- May 2022
- Primary completion
- Jul 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of maribavir in cytomegalovirus infection (CMV) (6 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration and 1 more. Started May 2022; status: completed.
02
Drugs
maribavir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT05382104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05382104.